Collegium Pharmaceutical (COLL) Non-Current Deffered Revenue (2024 - 2026)

Collegium Pharmaceutical's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $8.9 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue fell 10.56% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $8.9 million (down 10.56% YoY), while the FY2025 annual figure was $9.1 million, down 8.89% from the prior year.
• Non-Current Deffered Revenue was $8.9 million for Q1 2026 at Collegium Pharmaceutical, down from $9.1 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $10.0 million in Q3 2024 to a low of $8.9 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $9.6 million across 3 years, with a median of $10.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue retreated 7.22% in 2025, then declined 10.56% in 2026.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $10.0 million in 2024, then fell by 8.89% to $9.1 million in 2025, then fell by 1.83% to $8.9 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $8.9 million (Q1 2026), $9.1 million (Q4 2025), and $9.3 million (Q3 2025), per Business Quant data.